Aktienanalyse wird geladen …
KKR · NYSE · Asset Management · USA
96,67 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 19,46 Mrd. | 2,37 Mrd. | 2,34 $ | 890,34 Mio. | 7,5 Mio · 0,8 % | 4,1 Mio · 0,5 % | 18 % | 12,2 % | 0,36 $ | 0,81 $ | 0,73 $ |
| 2024 | 21,88 Mrd. | 3,08 Mrd. | 3,28 $ | 887,02 Mio. | 7,7 Mio · 0,9 % | — | 17,8 % | 14,1 % | 7,34 $ | 0,84 $ | 0,69 $ |
| 2023 | 14,5 Mrd. | 3,73 Mrd. | 4,09 $ | 867,5 Mio. | 6,4 Mio · 0,7 % | — | 33,9 % | 25,7 % | -1,85 $ | 0,71 $ | 0,65 $ |
| 2022 | 5,7 Mrd. | -521,66 Mio. | -0,79 $ | 749,5 Mio. | 7,6 Mio · 1 % | — | 36,1 % | -9,2 % | -7,16 $ | 0,97 $ | 0,61 $ |
| 2021 | 16,23 Mrd. | 4,73 Mrd. | 7,42 $ | 582,26 Mio. | 5,5 Mio · 0,9 % | — | 42,8 % | 29,2 % | -12,50 $ | 0,91 $ | 0,58 $ |
| 2020 | 4,23 Mrd. | 2 Mrd. | 3,37 $ | 562,81 Mio. | 3,4 Mio · 0,6 % | — | 49,1 % | 47,3 % | -10,85 $ | 0,58 $ | 0,53 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge |
|---|---|---|---|---|---|
| Q2 2026 | 5,73 Mrd. | 700,48 Mio. | 0,78 $ | — | 12,2 % |
| Q1 2026 | 4,32 Mrd. | 405,23 Mio. | 0,45 $ | — | 9,4 % |
| Q4 2025 | 5,74 Mrd. | 1,15 Mrd. | 1,16 $ | — | 20 % |
| Q3 2025 | 5,53 Mrd. | 900,36 Mio. | 1,00 $ | — | 16,3 % |
| Q2 2025 | 5,09 Mrd. | 510,12 Mio. | 0,57 $ | — | 10 % |
| Q1 2025 | 3,11 Mrd. | -185,92 Mio. | -0,21 $ | 888,25 Mio. | -6 % |
| Q4 2024 | 3,26 Mrd. | 1,13 Mrd. | 1,25 $ | — | 34,5 % |
| Q3 2024 | 4,79 Mrd. | 600,55 Mio. | 0,67 $ | — | 12,5 % |
Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-editing genetic medicines for rare and more common diseases. The company’s programs are designed to make precise changes at the RNA level, aiming to address disease-causing biology without permanently altering DNA. Its current pipeline includes lead candidate KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide under development for hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy, along with additional research programs in liver and other therapeutic areas. Korro Bio’s platform is built around programmable RNA editing and oligonucleotide-based delivery, positioning the company within the growing field of next-generation genetic medicines. Based in Cambridge, Massachusetts, Korro Bio focuses on discovery and development activities across its research and clinical-stage portfolio.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest KKR und jede andere Aktie unbegrenzt.